Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Preoperative nivo/ipi yields high response rate in early-stage colon cancer

Publish date:: April 13, 2020

Key clinical point: Preoperative nivolumab plus ipilimumab appears safe and active in patients with early-stage colon cancer.

Major finding: Pathological responses occurred in 100% of patients with mismatch repair–deficient tumors and in 27% of patients with mismatch repair–proficient tumors. Grade 3-4 treatment‐related adverse events were reported in 13% of patients.

Study details: A phase 2 trial of 40 patients with resectable, early-stage colon adenocarcinoma.

Disclosures: The study was sponsored by the Netherlands Cancer Institute in collaboration with Bristol-Myers Squibb. Authors reported financial relationships with Bristol-Myers Squibb and many other companies.

Citation:

Chalabi M et al. Nat Med. 2020 Apr 6. doi: 10.1038/s41591-020-0805-8.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,